IGC Pharma, Inc. (IGC)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $20.54M
Last updated: Nov 17, 2026 at 11:05 AM ET
IGC Pharma, Inc. (IGC) Competitors
The companies most similar to IGC Pharma are Dyadic International (DYAI), INmune Bio (INMB) and Edesa Biotech (EDSA). By market cap, IGC Pharma ranks 8th of the 13 companies on this page; iBio, Inc. Common Stock (IBIO) is the largest at $51.55M.
Peer Comparison
IGC's revenue growth of -19.2% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| IGC Pharma (IGC) | $20.54M | N/A | N/A | 0.0% | N/A | -19.2% | 0.00% |
| Dyadic International Inc (DYAI) | $13.10M | N/A | 4.4x | -200.5% | -224.8% | -0.6% | 0.00% |
| INmune Bio Inc (INMB) | $32.51M | N/A | N/A | 0.0% | N/A | 257.1% | 0.00% |
| Edesa Biotech Inc (EDSA) | $26.21M | N/A | N/A | 0.0% | N/A | -99.9% | 0.00% |
| Estrella Immunopharma Inc. (ESLA) | $22.36M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Hyperion DeFi, Inc. (HYPD) | $39.84M | N/A | 20.3x | 474.9% | 22.2% | 1560.0% | 0.00% |
| Citius Pharmaceuticals Inc (CTXR) | $14.69M | N/A | 1.9x | 0.0% | -84.3% | 0.0% | 0.00% |
| Cocrystal Pharma Inc (COCP) | $18.88M | N/A | 39.2x | 0.0% | N/A | 26.9% | 0.00% |
| Pluri Inc. (PLUR) | $15.09M | N/A | 8.7x | 0.0% | -650.8% | -15.8% | 0.00% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $36.15M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Collplant Biotechnologies Ltd (CLGN) | $14.27M | N/A | 21.0x | 0.0% | N/A | -39.7% | 0.00% |
| ProMIS Neurosciences Inc. (PMN) | $29.60M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| iBio, Inc. Common Stock (IBIO) | $51.55M | N/A | 735.4x | 0.0% | N/A | 975.0% | 0.00% |
| Peer median | $24.29M | N/A | 20.3x | 0.0% | -154.5% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to IGC Pharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Dyadic International Inc (DYAI) | Dyadic International, Inc., a biotechnology platform company, develops, produces and sells enzymes and other proteins in the United States. | DYAI competitors |
| INmune Bio Inc (INMB) | INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease... | INMB competitors |
| Edesa Biotech Inc (EDSA) | Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, is engaged in the research and development... | EDSA competitors |
| Estrella Immunopharma Inc. (ESLA) | Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. | ESLA competitors |
| Hyperion DeFi, Inc. (HYPD) | Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. | HYPD competitors |
| Citius Pharmaceuticals Inc (CTXR) | Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. | CTXR competitors |
| Cocrystal Pharma Inc (COCP) | Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic... | COCP competitors |
| Pluri Inc. (PLUR) | Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy... | PLUR competitors |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human... | TELO competitors |
| Collplant Biotechnologies Ltd (CLGN) | CollPlant Biotechnologies Ltd., an aesthetic and regenerative medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs... | CLGN competitors |
| ProMIS Neurosciences Inc. (PMN) | ProMIS Neurosciences Inc. is a pioneering biotechnology company focused on the development of innovative therapeutic solutions for neurodegenerative diseases... | PMN competitors |
| iBio, Inc. Common Stock (IBIO) | iBio, Inc., a biotech company, provides contract development and manufacturing services to outside partners and customers in the United States. | IBIO competitors |
Frequently Asked Questions About IGC
Who are IGC Pharma's main competitors?
The companies most similar to IGC Pharma include Dyadic International (DYAI), INmune Bio (INMB), Edesa Biotech (EDSA), Estrella Immunopharma (ESLA) and Hyperion DeFi (HYPD), listed from the closest match.
Who is IGC Pharma's biggest competitor?
iBio, Inc. Common Stock (IBIO) is the largest of the similar companies at $51.55M; Dyadic International (DYAI) is the closest match by business profile, size, sector and industry.
How does IGC stock compare with its competitors?
IGC's net margin is 0.0% against a peer median of 0.0%.
Which of IGC Pharma's competitors pays a higher dividend?
IGC Pharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is IGC Pharma bigger than its competitors?
No. IGC Pharma is 8th by market cap among the 13 companies on this page; the largest is iBio, Inc. Common Stock (IBIO) at $51.55M.
IGC pages: Overview, Earnings, Forecast, Financials, Competitors